CCR1 antagonist 9

Cat. No.: HY-124759

CAS No.: 1220026-26-5

Molecular Formula: $C_{20}H_{16}FN_5O_3S$

Molecular Weight: 425.44

Target: CCR

Pathway: GPCR/G Protein; Immunology/Inflammation

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : 83.33 mg/mL (195.87 mM; Need ultrasonic)

Preparing Stock Solutions

Solvent / Mass / Concentration	1 mg	5 mg	10 mg
1 mM	2.3505 mL	11.7525 mL	23.5051 mL
5 mM	0.4701 mL	2.3505 mL	4.7010 mL
10 mM	0.2351 mL	1.1753 mL	2.3505 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.08 mg/mL (4.89 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.08 mg/mL (4.89 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

CCR1 antagonist 9 is a potent and selective CCR1 antagonist with an IC_{50} of 6.8 nM in calcium flux assay[1].

IC_{50} & Target

CCR1
6.8 nM (IC_{50}, in calcium flux assay)

In Vitro

CCR1 antagonist 9 (Compound 19e) blocks the CCR1 chemotaxis of THP-1 cells with an IC_{50} of 28 nM. CCR1 antagonist 9 also blocks hERG with an IC_{50} of 30 μM[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Harcken C, et al. Identification of novel azaindazole CCR1 antagonist clinical candidates. Bioorg Med Chem Lett. 2019 Feb 1;29(3):441-448.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA